Tianyu Pharmaceutical: Wholly-owned subsidiary Obtains Drug Registration Certificate for Quetiapine Hydrochloride Tablets

Tianyu Pharmaceutical announced that its wholly-owned subsidiary Nuode Pharmaceutical recently received the salt citalopram tablets "Drug Registration Certificate" issued by the National Medical Products Administration, with a specification of 50mg and a validity period until December 15, 2030, suitable for the treatment of depression. As of the date of the announcement, there are several other domestic enterprises producing the same formulation, with estimated sales in domestic sample hospitals and physical pharmacies of approximately 596 million yuan in 2024. As of November 30, 2025, the company and its subsidiaries have cumulatively invested about 6.1734 million yuan in the research and development of this product. The approval of this product is expected to increase the company's revenue in the formulation business, but there are uncertainties in production, sales, and profitability levels.